Searchable abstracts of presentations at key conferences in endocrinology

ea0013p117 | Comparative | SFEBES2007

Performance characteristics of an intact PTH recently developed for the Abbott Architect immunoassay analyser

Smith Karen , Wallace Mike , Louden Ian

Concerns on the noncomparibility of intact parathyroid hormone (iPTH) methods have recently been voiced (Cantor T et al; Clin Chem 2006, 52, 1771–6). It is therefore important that any new iPTH immunoassays are thoroughly validated before routine use. We describe performance characteristics for an iPTH immunoassay on the ARCHITECT 8200i analyser as compared with iPTH measurement on the Diasorin LIAISON platform. Potassium EDTA plasma samples (n=80) we...

ea0094p324 | Bone and Calcium | SFEBES2023

Age-specific reference intervals of Abbott intact parathyroid hormone (PTH) in adults

Kalaria Tejas , Lawson Alexander , Duffy Joanne , Agravatt Ashishkumar , Harris Steve , Ford Clare , Gama Rousseau , Webster Craig , Gittoes Neil

Background: Assays for parathyroid hormone (PTH) are not standardized and therefore method-specific reference intervals are necessary for interpretation of results. PTH increases with age in adults but age-specific reference intervals for the Abbott intact PTH (iPTH) assay are not available. It is challenging and resource intensive to derive age-specific reference intervals by direct method because, depending on number of age partitions, samples from a large n...

ea0031p39 | Clinical biochemistry | SFEBES2013

Cross-reactivity of ten recombinant insulin preparations in the Abbott Architect Insulin immunoassay

Clarke Catriona , Shearing Catherine

Preparations of recombinant insulin and insulin analogues are used in the treatment of insulin-dependent diabetes. Recombinant insulin that corresponds to the human sequence might be expected to cross-react extensively with insulin assays. Insulin analogues contain modifications that alter their action profiles and may therefore interact unpredictably with detection antibodies. In the differential diagnosis of hypoglycaemia it is important to be aware of the extent of the cros...

ea0086p95 | Neuroendocrinology and Pituitary | SFEBES2022

Optimising the Insulin Tolerance Test: Cortisol Thresholds on Abbott Platforms should be lowered to 416 nmol/L

Hayes Annabel , Choudhury Sirazum , Lazarus Katharine , Meeran Karim

Background: Adrenal insufficiency (AI) is a life-threatening condition which requires long term glucocorticoid (GC) replacement. Patient misdiagnosis results in inappropriate GC use, which has significant adverse effects and is associated with an increased mortality risk. The insulin tolerance test (ITT) is the gold standard test for diagnosis, but the widely accepted cut-off value of ≤550 nmol/l used to diagnose AI is founded on outdated immunoassays. Use of this cut-of...

ea0011p898 | Thyroid | ECE2006

Multicenter evaluation of the Abbott ARCHITECT® anti-Tg and anti-TPO assays

Anarat R , Bena C , Garth H , Klein M , Radicioni A , Schmitt S , Smith C , Szepanski S , Turanchik M , Waterston J

The purpose of these studies was to conduct a multi-center evaluation of the performance of the new Abbott ARCHITECT Anti-Tg and Anti-TPO assays. Both assays are two-step, chemiluminescent, microparticle-based immunoassay for the quantitative determination of either the IgG class of thyroglobulin autoantibodies (anti-Tg) or the IgG class of thyroid peroxidase autoantibodies (anti-TPO) in human serum and plasma. The ARCHITECT Anti-Tg and Anti-TPO assays are designed to have a d...

ea0009p64 | Growth and development | BES2005

Epigenetic programming of the human endothelial nitric oxide pathway

Abbott L , Newell-Price J

Background - Adverse fetal nutritional supply results in programmed endothelial dysfunction and hypertension in offspring. Nitric Oxide Synthase (eNOS), Endothelin-1 (ET-1), and human Cationic Amino acid Transporter-1 (hCAT-1) are key players in endothelial function. We have shown that hCAT-1 is down-regulated in smaller neonates. One possible explanatory mechanism is DNA methylation, which reduces gene expression. In mice and rat models maternal diets with altered leve...

ea0011p738 | Steroids | ECE2006

Long-term glucocorticoid repression of pro-opiomelanocortin (POMC) expression

Eltobgi A , Abbott L , Newell-Price J

Background: A functioning Hypothalamo-pituitary-adrenal (HPA) axis is essential for life. Prolonged high circulating levels of glucocorticoids inhibit pituitary Pro-opiomelanocortin (POMC) gene expression. Repression continues even in the absence of continued glucocorticoid exposure. To date there are no molecular explanations for this observation.Hypothesis: Long-term exposure to glucocorticoids causes de-novo DNA methylation of the pituit...

ea0015p236 | Pituitary | SFEBES2008

Locked nucleic acid modified siRNAs maintain efficacy of gene silencing, but have reduced serum stability in a model of Cushing’s disease

Munir Alia , Eltobgi Adim , Abbott Lee , Newll-Price John

Introduction: POMC is activated in ACTH-dependent Cushing’s Syndrome. We have previously shown that RNA interference (RNAi) targeting POMC coding and promoter sequences induces silencing of POMC and a reduction in ACTH. We have modified our most potent exonic sequence with locked nucleic acid (LNA) chemistry. This is purported to increase serum stability. Here we test whether the LNA confers stability without compromising siRNA silencing potency.<...

ea0013p248 | Neuroendocrinology and behaviour (including pituitary) | SFEBES2007

RNA interference as a therapy for a model of Cushing’s disease

Munir Alia , Eltobgi AbdulAdim , Abbott Lee , Newell-Price John

Introduction: Pro-opiomelanocortin (POMC) is a precursor polypeptide which is cleaved to make adrenocorticotrophic hormone (ACTH) in the anterior pituitary. It is activated in Cushing’s disease. Current therapies for Cushing’s disease are inadequate. RNA interference (RNAi) allows highly specific and effective suppression of gene expression by use of short interfering RNAs (siRNAs).Method: In the current study we employed custom designed siRNAs...

ea0003oc48 | Neuroendocrinology | BES2002

Hypothalamic actions of Neuromedin U

Wren A , Small C , Abbott C , Ghatei M , Bloom S

The CNS and gut derived peptide Neuromedin U (NMU) has been shown to inhibit feeding following intracerebroventricular (ICV) injection. The present study aimed to further explore the hypothalamic actions of NMU. ICV NMU-23 (1nmol), but not truncated NMU-8, significantly inhibited feeding (1h food intake: 3.8 plus/minus 0.4g vs saline 5.4 plus/minus 0.6g, p <0.05). Following micro-injection into 8 hypothalamic areas, NMU-23 potently inhibited feeding in the PVN (1h food int...